In the past 70 years,drug therapy for depression has been based on the monoamine hypothesis.In recent years,people have shifted their focus from monoamine targets to the development of multi target reuptake inhibitors and non monoamine target drugs.This article reviews the relatively new antidepressant drugs that have entered clinical practice or have been marketed in recent years:preclinical mechanism research and clinical efficacy evaluation of hypidone hydrochloride,toludesvenlafaxine hydrochloride,psilocybin,ketamine/S-ketamine,dextromethorphan-bupropion,brexanolone/zuranolone,summarizing the research progress of depression drug treatment in recent years,hoping to provide direction for the next step of depression drug research.
万方数据
维普
